New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year
This article was originally published in Clinica
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) wants to charge an annual fee to manufacturers to pay for its market surveillance activities, but is expected to issue a 12-week public consultation first. The exact level of fee is not yet known but is expected to be in the region of 0.12% of turnover, Mike Kreuzer, regulatory director of the Association of British Healthcare Industries told delegates at the Bristows/ABHI medical device meeting in London on April 21.
Register for our free email digests: